Download Acute Lymphoblastic Leukemia

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Acute
Lymphoblastic
Leukemia
Maggie Davis Hovda
5/26/2009
Definition
Neoplastic disease which results from a
mutation in a single lymphoid progenitor
cell at one of several discrete stages of
development
 B Cell or T Cell

Epidemiology
Most common childhood acute leukemia,
~80%
 Incidence in adults ~20%
 Bimodal distribution of occurrence:

 Peak
at age 2-5
 Second increased incidence after age 50
Pathogenesis

Acquired Genetic Change in Chromosome
 Change
in number, ie ploidy
 Change in structure





Translocations (most common)
Inversions
Deletions
Point mutations
Amplifications
Changes in normal means of cell differentiation, proliferation, and
survival
Mechanisms of Leukemia Induction

1 – Activation of a protooncogene OR creation of
a fusion gene with
oncogenic properties
- Ph Chromosome t(9;22)
2 – Loss or inactivation
of ≥ 1 tumor
suppressor gene
- p53 (p16 mutation)
Etiology


Unknown
? Genetic Predisposition



Down Syndrome
Disorder with chromosomal fragility:




Increased incidence amongst monozygotic and dizygotic twins
Fanconi’s anemia
Bloom Syndrome
Ataxia-Telangiectasia
? Infections



HTLV1 in T cell leukemia/lymphoma
EBV in mature B cell ALL
HIV in lymphoproliferative DO
Presentation

Nonspecific Symptoms
 Fatigue/decreased
energy
 Fever
 Easy
bruising
 Bleeding
 Dyspnea
 Dizziness
 Infection


Joint, extremity pains
CNS involvement
Clinical Presentation

Physical Exam

Lab Abnormalities
 Pallor
 anemia
 Ecchymoses
 wbc
 Petechiae
 LAD
 Hepatosplenomegaly
0.1 (20-40%) - >100 k
(10-16%)
Platelets – usually ↓
↑ LD, uric acid
CXR: eval for thymic mass
CSF to eval for
involvement





vary
Diagnosis

Morphologic
 French
American British Classification
L1: small uniform blasts (pediatric ALL)
 L2: larger, more variable sized blasts (adult ALL)
 L3: uniform cells with basophilic and sometimes
vacuolated cytoplasm (mature B cell ALL)

Immunophenotyping
From: Jabbour, E. et al. Adult Acute Lymphoblastic
Leukemia. Mayo Clinic Proc. 2005;80(11):1517-1527
Cytogenetic Abnormalities
From: Jabbour, E. et al. Adult Acute Lymphoblastic
Leukemia. Mayo Clinic Proc. 2005;80(11):1517-1527

Classification of ALL
Immunologic
Subtype
% of cases
FAB Subtype
Cytogenetic
Abnormalities
Pre-B ALL
75
L1, L2
t(9;22), t(4;11),
t(1;19)
T cell ALL
20
L1, L2
14q11 or 7q34
B cell ALL
5
L3
t(8;14), t(8;22),
t(2;8)
From: Harrison’s Principles of Internal Medicine, 16th
ed. 2005. Chapter 97, Malignancies of lymphoid cells.
Differential Diagnosis
ITP
 Aplastic Anemia
 Infectious mononucleosis
 Rheumatoid Arthritis
 Rheumatic Fever
 Collagen Vascular Disease

Treatment
1 – Remission Induction
 2 – Intensification (Consolidation) Therapy
 3 – Maintenance Therapy
 4 – CNS Prophylaxis
 5 – Allogeneic Stem Cell Transplant

Treatment

Remission Induction
 Goals:
restore normal hematopoiesis, induce a
complete remission rapidly in order to prevent
resistance to drugs
 Standard induction regimen


4 or 5 drugs: vincristine, prednisone, anthracycline, Lasparaginase, +/- cyclophosphamide
Intensification
 High
doses of multiple agents not used during
induction or re-administration of the induction regimen
Treatment

Maintenance Therapy
 Daily
po 6MP, weekly MTX, monthly pulses of
vincristine and prednisone for 2-3 yrs

CNS Prophylaxis
 Given
during induction and intensification
 Intrathecal: MTX, Cytarabine, corticosteroids
 Systemic: high dose mtx, cytarabine, L-asparaginase
 +/- Cranial Irradiation
Treatment

Stem Cell Transplant
 Done
during first CR
 Indications:




Ph Chromosome
t(4;11) mutation
Poor initial response to induction therapy
Other
 Adolescents
benefit significantly from pediatric ALL
regimens vs. adult regimens
Relapse & Prognosis

Relapse
 Most
occur during treatment or within the first 2 years
 Bone Marrow is the most common site
 Poor prognostic factors in patients previously treated:






Relapse on therapy
Short initial remission after intense therapy
T-cell immunophenotype
Ph Chromosome
Circulating blasts
High leukocyte count at relapse
Prognosis
Overall better in children than in adults
 In adults, worse outcomes with:

 Increasing
age, >60
 Increased wbc count at presentation
Sources




Jabbour, E. et al. Adult Acute Lymphoblastic Leukemia.
Mayo Clinic Proc. 2005;80(11):1517-1527
Xavier, T. Chemotherapy of acute leukemia in adults.
Expert Opin. Pharmacother. (2009) 10(2):221-237
Williams Hematology, 6th ed. 2001. Chapter 97, Acute
Lymphoblastic Leukemia.
Harrison’s Principles of Internal Medicine, 16th ed. 2005.
Chapter 97, Malignancies of lymphoid cells.